4-amino-N,N-dimethyl-3-nitrobenzamide | 726206-82-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-amino-N,N-dimethyl-3-nitrobenzamide
• CAS: 726206-82-2
• 化学式: C₉H₁₁N₃O₃
• mdl: MFCD16662367
• 分子量: 209.205
• InChiKey: KMZCYAYGNARDFM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  92.2
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-amino-N,N-dimethyl-3-nitrobenzamide 在 4-二甲氨基吡啶 、 iron(III) chloride 、 三乙胺 、 锌 作用下， 以 吡啶 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 为溶剂， 生成 N-[2-amino-4-(dimethylcarbamoyl)phenyl]-1-(benzenesulfonyl)-5-chloroindole-2-carboxamide
  参考文献：
  名称：

  Design, synthesis and SAR of novel ethylenediamine and phenylenediamine derivatives as factor Xa inhibitors

  摘要：

  We previously reported on a series of cyclohexanediamine derivatives as highly potent factor Xa inhibitors. Herein, we describe the modification of the spacer moiety to discover an alternative scaffold. Ethylenediamine derivatives possessing a substituent at the C1 position in S configuration and phenylenediamine derivatives possessing a substituent at the C5 position demonstrated moderate to strong anti-fXa activity. Further SAR studies led to the identification of compound 30h which showed both good in vitro activity (fXa IC50 = 2.2 nM, PTCT2 = 3.9 mu M) and in vivo antithrombotic efficacy. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.01.132
• 作为产物：
  描述：

  4-乙酰氨基-3-硝基苯甲酰氯 在 盐酸 作用下， 以 四氢呋喃 、 乙醇 、 水 为溶剂， 生成 4-amino-N,N-dimethyl-3-nitrobenzamide
  参考文献：
  名称：

  Design, synthesis and SAR of novel ethylenediamine and phenylenediamine derivatives as factor Xa inhibitors

  摘要：

  We previously reported on a series of cyclohexanediamine derivatives as highly potent factor Xa inhibitors. Herein, we describe the modification of the spacer moiety to discover an alternative scaffold. Ethylenediamine derivatives possessing a substituent at the C1 position in S configuration and phenylenediamine derivatives possessing a substituent at the C5 position demonstrated moderate to strong anti-fXa activity. Further SAR studies led to the identification of compound 30h which showed both good in vitro activity (fXa IC50 = 2.2 nM, PTCT2 = 3.9 mu M) and in vivo antithrombotic efficacy. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.01.132

文献信息

• [EN] HETEROCYCLIC COMPOUNDS AS INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS DU RÉCEPTEUR DU FACTEUR DE CROISSANCE DES FIBROBLASTES
  申请人：GUANGDONG NEWOPP BIOPHARMACEUTICALS CO LTD

  公开号：WO2020119606A1

  公开（公告）日：2020-06-18

  Disclosed are heterocyclic compounds as inhibitors of FGFR-4 represented by formula (I). Also disclosed is a pharmaceutical composition that includes an inhibitor of FGFR-4. The compounds maybe used to treat diseases mediated with abnormality of FGFR-4 and /or FGF19, such as hepatocellular carcinoma and other forms of cancer.

  本发明涉及一种以式(I)表示的FGFR-4抑制剂的杂环化合物。还公开了一种包含FGFR-4抑制剂的药物组合物。这些化合物可用于治疗由FGFR-4和/或FGF19异常介导的疾病，如肝细胞癌和其他形式的癌症。
• 4-羟基-N,N,2-三甲基苯并咪唑-6-甲酰胺的可放大生产方法
  申请人：深圳市华先医药科技有限公司

  公开号：CN115536593A

  公开（公告）日：2022-12-30

  一种合成4‑羟基‑N,N,2‑三甲基苯并咪唑‑6‑甲酰胺的方法，路线如下，本发明合成4‑羟基‑N,N,2‑三甲基苯并咪唑‑6‑甲酰胺的方法，具有工艺路线新颖、原料价廉易得、化学纯度≥99％、易于生产放大的特点。
• Design, synthesis and SAR of novel ethylenediamine and phenylenediamine derivatives as factor Xa inhibitors
  作者：Kenji Yoshikawa、Toshiharu Yoshino、Yoshihiro Yokomizo、Kouichi Uoto、Hiroyuki Naito、Katsuhiro Kawakami、Akiyoshi Mochizuki、Tsutomu Nagata、Makoto Suzuki、Hideyuki Kanno、Makoto Takemura、Toshiharu Ohta

  DOI：10.1016/j.bmcl.2011.01.132

  日期：2011.4

  We previously reported on a series of cyclohexanediamine derivatives as highly potent factor Xa inhibitors. Herein, we describe the modification of the spacer moiety to discover an alternative scaffold. Ethylenediamine derivatives possessing a substituent at the C1 position in S configuration and phenylenediamine derivatives possessing a substituent at the C5 position demonstrated moderate to strong anti-fXa activity. Further SAR studies led to the identification of compound 30h which showed both good in vitro activity (fXa IC50 = 2.2 nM, PTCT2 = 3.9 mu M) and in vivo antithrombotic efficacy. (C) 2011 Elsevier Ltd. All rights reserved.